Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

Early, sex-dependent and progressive proteomic imbalance in the amygdala during Alzheimer's disease continuum

  • Romero-Murillo, Silvia
  • Lachén Montes, Mercedes
  • Cartas Cejudo, Paz
  • Anaya-Cubero, Elena
  • Miguel, Marina de
  • Extramiana, Leire
  • Ferrer, Isidro
  • Fernández Irigoyen, Joaquín
  • Santamaría Martínez, Enrique
Background: The amygdala is involved in the emotional expression, memory processing and managing stimulatory input. Although amygdala atrophy is early evidenced in Alzheimer's Disease (AD), the molecular mechanisms disrupted in initial neuropathological stages are still unknown. In the present study, we investigated the proteomic impairment of the amygdaloid region from AD-Braak stage I-II and III-IV subjects to better understand the neuropathological processes occurred early in this area and to identify potential targets that may face AD from the beginning of the disease. Methods: Label-free quantitative proteomics was applied using an Orbitrap Exploris 480 mass-spectrometer in 24 postmortem amygdala specimens derived from non-demented (n = 3F/5M), AD-Braak stage I-II (n = 4F/4M) and AD-Braak stage III-IV (n = 4F/4M). Data analysis was performed using MaxQuant and Perseus software (two-way Student T-test; p < 0.05). Metascape and Ingenuity Pathway Analysis softwares were considered for biological interpretation. Connectivity map platform was used for drug repurposing analyses. Transcriptomic/proteomic data of other brain regions were obtained from AlzData, Neuropro, and Agora repositories. Results: Amygdaloid proteome of AD-Braak stage I-II and III-IV subjects compared to controls revealed a progressive proteomic impairment with a minimal overlap across Braak stages. Some of the amygdaloid DEPs were known interactors of human A¿ plaques, APP, or Tau proteins or were previously identified at transcriptional or translational level in other brain regions affected by AD. Interestingly, amygdaloid proteome was more severely affected in women than in men with a particular protein expression profile associated to each AD stage. Comparing our sex-dependent differential proteome datasets with transcriptomic data of different brain regions, we identified potential sex-specific proteins related to cognitive decline and neurodegeneration. Finally, data-driven drug repositioning using amygdaloid omics profiles unveiled that most of the small molecule candidates were neuropathological stage and/or sex-specific. Conclusions: Early and sex-specific amygdaloid proteome dysregulation in AD highlights the consideration of a deliberate stratification by sex in future research and clinical trials to develop effective therapeutic strategies in AD for both sexes. Plain english summary: The amygdala is a brain region involved in the expression of emotions, memory processing and managing incoming stimulus. Atrophy of this area is evidenced at the first stages of Alzheimer¿s Disease (AD), pointing out a potential involvement of amygdala in the pathology of this disease. However, the molecular changes occurred early in this area are not fully understood. To this end, we interrogated the proteome of amygdala postmortem samples came from subjects of early AD stages. By applying data and functional analyses, we observed a stage-dependent and progressive proteomic impairment in this area. We detected proteins differentially expressed that were already known to interact with well-stablished neuropathological proteins or were altered in other brain areas. Importantly, data stratification by sex revealed that protein expression changes of amygdala were more abundant in women than men across AD progression. After comparing our results with published data in different brain regions affected by AD, we identified sex-specific proteins that could be used as biomarkers of cognitive decline and neurodegeneration. Finally, a drug repositioning-based approach proposed candidates with the potential to reverse amygdaloid malignant AD signature more effectively in one sex than in other or just in one sex. These observations highlight the consideration to include sex differences in future research to develop more precise and effective treatments in AD., The Clinical Neuroproteomics Unit of Navarrabiomed is a member of the Spanish Olfactory Network (ROE) (supported by grant RED2022-134081-T funded by Spanish Ministry of Science and Innovation). The Clinical Neuroproteomics Unit is supported by grants PID2023-152593OB-I00 funded by MCIU/AEI/ 10.13039/501100011033 / FEDER, UE to ES and JFI and 0011-1411-2023-000028 (from Government of Navarra-Department of Economic and Business Development-S4) to ES. Paz Cartas-Cejudo is supported by a postdoctoral fellowship from Public University of Navarra (UPNA).
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Tesis doctoral (DoctoralThesis)

Decoding molecular olfactory alterations in neurodegeneration: sex differences and drug repurposing strategies in Alzheimer’s and Parkinson’s diseases

  • Cartas Cejudo, Paz
La disfunción olfativa es una característica temprana y común de las enfermedades neurodegenerativas (EN), particularmente de la enfermedad de Alzheimer (EA) y la enfermedad de Parkinson (EP), donde los cambios patológicos en las regiones de procesamiento olfativo, como el tracto olfativo (TO), contribuyen a los déficits en el sentido del olfato. Esta tesis tiene como objetivo explorar los mecanismos moleculares subyacentes a estos trastornos, utilizando proteómica de alto rendimiento para analizar muestras post-mortem del TO de sujetos con EA, EP y controles. El análisis de expresión proteica diferencial reveló alteraciones proteómicas significativas tanto en la EA como en la EP, con variaciones dependientes del sexo observadas, particularmente en la expresión de sirtuinas (SIRTs). De manera notable, las mujeres mostraron una disfunción proteómica más grave en comparación con los hombres, independientemente de la enfermedad, con patrones alterados de acetilación de proteínas en regiones olfativas clave en el cerebro. Además, establecimos un flujo de trabajo utilizando firmas ómicas olfativas y del tronco encefálico en un enfoque computacional, Connectivity Map (CMap), con el objetivo de obtener posibles dianas para el reposicionamiento de fármacos en EA y EP. Además, varias clases farmacológicas parecían ser candidatas potenciales para restaurar las firmas ómicas alteradas. La validación in vitro confirma que varios de los inhibidores propuestos ejercieron efectos neuroprotectores, reduciendo el daño por estímulos neuropatológicos y la toxicidad por estrés oxidativo. Estos hallazgos subrayan el valor de la proteómica olfativa para entender los mecanismos moleculares específicos del sexo en la EA y la EP, y sugieren que las firmas ómicas podrían servir como plantilla para desarrollar nuevas estrategias terapéuticas frente a los síndromes neurológicos., Olfactory dysfunction is an early and common feature of neurodegenerative diseases (NDs), particularly Alzheimer’s disease (AD) and Parkinson’s disease (PD), where pathological changes in olfactory processing regions, such as the olfactory tract (OT) contribute to deficits in smell. This thesis aimed to explore the molecular mechanisms underlying these impairments, using high-throughput proteomics to analyze post-mortem OT samples from AD, PD, and control subjects. Differential protein expression analysis revealed significant proteomic alterations in both AD and PD, with sex-dependent variations observed, particularly in the expression of sirtuins (SIRTs). Notably women showed more severe proteomic dysregulation compared to men, regardless of the disease, with altered protein acetylation patterns in key olfactory brain regions. Moreover, we established a workflow using olfactory and brainstem omics signatures in a computational approach, Connectivity Map (CMap), with the aim of obtaining potential targets for drug repurposing in AD and PD. Furthermore, various pharmacological classes seemed to be potential candidates to restore disrupted omics signatures. In vitro validation confirmed that several of the proposed inhibitors exerted neuroprotective effects, reducing damage from neuropathological insults and oxidative stress toxicity. These findings underscore the value of olfactory proteomics in understanding sex-specific molecular mechanisms in AD and PD and suggest that omics signatures could serve as a template for developing novel therapeutic strategies against neurological syndromes., Ayudas y financiaciones que han permitido el desarrollo de esta tesis: Referencia: 0011-1411-2020-000028. Entidad: Departamento de Desarrollo Económico y Empresarial (Estratégicos S3) del Gobierno de Navarra. Convocatoria 2020 de ayudas a proyectos estratégicos de I+D. Título: INNOLFACT. Implementación de medicina de precisión olfatoria y desarrollo de terapias nasales inmunomoduladores en envejecimiento y neurodegeneración. Duración: 2020-2022; Referencia: 0011-1411-2023-000028. Entidad: Departamento de Desarrollo Económico y Empresarial (Estratégicos S4) del Gobierno de Navarra. Convocatoria 2023-2026 de ayudas a proyectos estratégicos de I+D. Título: INNOLFACT 2.0: Combinación de Inteligencia Artificial y Reposicionamiento de Fármacos en Medicina de Precisión Olfatoria Duración: 2023-2025; Referencia: PID2023-152593OB-I00. Entidad: AEI. Proyectos de Generación de Conocimiento» del Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia, en el marco del Plan Estatal de Investigación Científica, Técnica y de Innovación 2021-2023. Título: INTERFERENCIA ENTRE LA ACETILACION Y LA FOSFORILACION EN LA ENFERMEDAD DE ALZHEIMER: PAPEL DE LAS SIRTUINAS 3 Y 7 EN NEURODEGENERACION OLFATORIA., Programa de Doctorado en Ciencias de la Salud (RD 99/2011), Osasun Zientzietako Doktoretza Programa (ED 99/2011)
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

Effect of immunology biomarkers associated with hip fracture and fracture risk in older adults

  • Cedeño Veloz, Bernardo Abel
  • Lozano Vicario, Lucía
  • Zambom Ferraresi, Fabrício
  • Fernández Irigoyen, Joaquín
  • Santamaría Martínez, Enrique
  • Rodríguez-García, Alba
  • Romero Ortuno, Román
  • Mondragón Rubio, Jaime
  • Ruiz-Ruiz, Javier
  • Ramírez Vélez, Robinson
  • Izquierdo Redín, Mikel
  • Martínez Velilla, Nicolás
Osteoporosis is a skeletal disease that can increase the risk of fractures, leading to adverse health and socioeconomic consequences. However, current clinical methods have limitations in accurately estimating fracture risk, particularly in older adults. Thus, new technologies are necessary to improve the accuracy of fracture risk estimation. In this observational study, we aimed to explore the association between serum cytokines and hip fracture status in older adults, and their associations with fracture risk using the FRAX reference tool. We investigated the use of a proximity extension assay (PEA) with Olink. We compared the characteristics of the population, functional status and detailed body composition (determined using densitometry) between groups. We enrolled 40 participants, including 20 with hip fracture and 20 without fracture, and studied 46 cytokines in their serum. After conducting a score plot and two unpaired t-tests using the Benjamini-Hochberg method, we found that Interleukin 6 (IL-6), Lymphotoxin-alpha (LT-α), Fms-related tyrosine kinase 3 ligand (FLT3LG), Colony stimulating factor 1 (CSF1), and Chemokine (C-C motif) ligand 7 (CCL7) were significantly different between fracture and non-fracture patients (p < 0.05). IL-6 had a moderate correlation with FRAX (R2 = 0.409, p < 0.001), while CSF1 and CCL7 had weak correlations with FRAX. LT-α and FLT3LG exhibited a negative correlation with the risk of fracture. Our results suggest that targeted proteomic tools have the capability to identify differentially regulated proteins and may serve as potential markers for estimating fracture risk. However, longitudinal studies will be necessary to validate these results and determine the temporal patterns of changes in cytokine profiles., Open Access funding provided by Universidad Pública de Navarra. Funding for this project came from NM-V received funding from the “La Caixa” Foundation (ID 100010434), under agreement LCF/PR/PR15/51100006. ES also received funding from the grant from Department of Economic and Business Development from Government of Navarra (Ref. 0011-1411-2023-000028).
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

Impact of medication use on olfactory performance in older adults

  • Izco-Cubero, Maite
  • Zambom Ferraresi, Fabíola
  • Zambom Ferraresi, Fabrício
  • Fernández González de la Riva, María Luisa
  • Santamaría Martínez, Enrique
  • Fernández Irigoyen, Joaquín
  • Lachén Montes, Mercedes
  • Lasarte, Juan José
  • Uzcanga Lacabe, María Iciar
  • Fernández, Secundino
  • Sanjurjo San Martín, Gloria
  • Maravi Aznar, Enrique
  • Martínez Velilla, Nicolás
Introduction: Olfactory dysfunction impacts quality of life, safety, and nutrition. Despite its relevance among older adults, the role of medications in influencing olfactory performance remains understudied. This research investigates whether olfactory alterations in older adults are associated with the type or number of medications prescribed. Methods: An observational cross-sectional study was conducted with 107 participants (mean age of 86.1 ± 5.1 years). Olfactory performance was evaluated using the Sniffin’ Sticks Test (SST). Functional capacity, cognitive function and the number and type of medications were also assessed. Results: The analysis demonstrated a correlation between better olfactory performance and higher cognitive function. An inverse correlation was found between the age of participants and olfactory identification. While polypharmacy (intake of five or more medications) did not show a significant association with olfactory dysfunction, the intake of laxatives was associated with poorer olfactory threshold performance (−1.21, 95% CI −2.07 to −0.34; p = 0.008). In contrast, proton pump inhibitors (PPIs) (1.14, 95% CI 0.07 to 2.21; p = 0.04) and vitamin D (1.09, 95% CI 0.03 to 2.15; p = 0.04) intake were linked to improved olfactory identification. Discussion: These findings suggest that certainmedications influence olfactory performance; however, further research is needed to clarify the effects of different drug classes on olfaction., The Clinical Neuroproteomics Unit is member of the Spanish Olfactory Network -ROE (grant RED2022-134081-T from the Spanish Ministry of Science & Innovation) and is supported by grants PID2023-152593OB-I00 funded by MCIU/AEI/ 10.13039/501100011033 / FEDER, UE to and 0011-1411-2023-000028 from Government of Navarra (Department of Economic and Business Development-S4).
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

Neuropathological stage-dependent proteome mapping of the olfactory tract in Alzheimer's disease: from early olfactory-related omics signatures to computational repurposing of drug candidates

  • Cartas Cejudo, Paz
  • Cortés, Adriana
  • Lachén Montes, Mercedes
  • Anaya-Cubero, Elena
  • Puerta, Elena
  • Solas, Maite
  • Fernández Irigoyen, Joaquín
  • Santamaría Martínez, Enrique
Alzheimer's disease (AD) is the most common form of dementia, characterized by an early olfactory dysfunction, progressive memory loss, and behavioral deterioration. Albeit substantial progress has been made in characterizing AD-associated molecular and cellular events, there is an unmet clinical need for new therapies. In this study, olfactory tract proteotyping performed in controls and AD subjects (n = 17/group) showed a Braak stage-dependent proteostatic impairment accompanied by the progressive modulation of amyloid precursor protein and tau functional interactomes. To implement a computational repurposing of drug candidates with the capacity to reverse early AD-related olfactory omics signatures (OMSs), we generated a consensual OMSs database compiling differential omics datasets obtained by mass-spectrometry or RNA-sequencing derived from initial AD across the olfactory axis. Using the Connectivity Map-based drug repurposing approach, PKC, EGFR, Aurora kinase, Glycogen synthase kinase, and CDK inhibitors were the top pharmacologic classes capable to restore multiple OMSs, whereas compounds with targeted activity to inhibit PI3K, Insulin-like growth factor 1 (IGF-1), microtubules, and Polo-like kinase (PLK) represented a family of drugs with detrimental potential to induce olfactory AD-associated gene expression changes. To validate the potential therapeutic effects of the proposed drugs, in vitro assays were performed. These validation experiments revealed that pretreatment of human neuron-like SH-SY5Y cells with the EGFR inhibitor AG-1478 showed a neuroprotective effect against hydrogen peroxide-induced damage while the pretreatment with the Aurora kinase inhibitor Reversine reduced amyloid-beta (Aβ)-induced neurotoxicity. Taken together, our data pointed out that OMSs may be useful as substrates for drug repurposing to propose novel neuroprotective treatments against AD., Spanish Ministry of Science, Innovation and Universities, Grant/Award Number: PID2019-110356RB-I00/AEI/10.13039/501100011033; Department of Economic and Business Development from Government of Navarra, Grant/Award Number: 0011-1411-2023-000028; Public University of Navarra (UPNA); Miguel Servet Foundation-Navarrabiomed; Programa MRR Investigo 2023
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

The potential of proteomics for in-depth molecular investigations of progressive supranuclear palsy

  • Romero-Murillo, Silvia
  • Lee, Seojin
  • Fernández Irigoyen, Joaquín
  • Martínez-Valbuena, Iván
  • Santamaría Martínez, Enrique
Introduction: progressive supranuclear palsy (PSP) is a rare neurodegenerative disorder. The lack of comprehension about the pathogenesis of the disease, its heterogeneity, and the complex clinical evaluation in early stages, limit the development of effective treatments for PSP patients and highlight the need of further research on the field. Areas covered: in this work, we review the current knowledge of the physio- and neuropathology of PSP, its clinical features, diagnosis markers, and treatment options. We also compare the proteomic-based studies done to date in brain tissues as well as in cerebrospinal fluid and other non-cerebral samples, briefly describing the proteomic approach used and the biological findings obtained in each study. Expert opinion: PSP is a complex neurodegenerative disorder marked by tau aggregation, glial dysfunction, and neuroinflammation. Although advances in neuroimaging and biofluid biomarkers have improved PSP diagnostic accuracy, no disease-modifying therapies are currently available. Promising avenues such as tau PET tracers, seed amplification assays, and advanced proteomic-based approaches are enhancing our ability to detect disease-specific tau pathology and hold the potential to provide novel biomarkers for earlier and more precise clinical diagnosis and treatment development that could transform the landscape of PSP., The Clinical Neuroproteomics Unit is supported by grants PID2023-152593OB-I00 funded by MCIU/AEI/10.13039/501100011033/FEDER, UE to ES and JFI and 0011-1411-2023-000028 (from Government of Navarra- Department of Economic and Business Development-S4).
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

Involvement of glucosamine 6 phosphate isomerase 2 (GNPDA2) overproduction in beta-amyloid- and Tau P301L-driven pathomechanisms

  • Lachén Montes, Mercedes
  • Cartas Cejudo, Paz
  • Cortés, Adriana
  • Anaya-Cubero, Elena
  • Peral, Erika
  • Ausín, Karina
  • Díaz-Peña, Ramón
  • Fernández Irigoyen, Joaquín
  • Santamaría Martínez, Enrique
Alzheimer’s disease (AD) is a neurodegenerative olfactory disorder affecting millions of people worldwide. Alterations in the hexosamine- or glucose-related pathways have been described through AD progression. Specifically, an alteration in glucosamine 6 phosphate isomerase 2 (GNPDA2) protein levels has been observed in olfactory areas of AD subjects. However, the biological role of GNPDA2 in neurodegeneration remains unknown. Using mass spectrometry, multiple GNPDA2 interactors were identified in human nasal epithelial cells (NECs) mainly involved in intraciliary transport. Moreover, GNPDA2 overexpression induced an increment in NEC proliferation rates, accompanied by transcriptomic alterations in Type II interferon signaling or cellular stress responses. In contrast, the presence of beta-amyloid or mutated Tau-P301L in GNPDA2-overexpressing NECs induced a slowdown in the proliferative capacity in parallel with a disruption in protein processing. The proteomic characterization of Tau-P301L transgenic zebrafish embryos demonstrated that GNPDA2 overexpression interfered with collagen biosynthesis and RNA/protein processing, without inducing additional changes in axonal outgrowth defects or neuronal cell death. In humans, a significant increase in serum GNPDA2 levels was observed across multiple neurological proteinopathies (AD, Lewy body dementia, progressive supranuclear palsy, mixed dementia and amyotrophic lateral sclerosis) (n = 215). These data shed new light on GNPDA2-dependent mechanisms associated with the neurodegenerative process beyond the hexosamine route., This work was funded by grants from the Spanish Ministry of Science, Innovation and Universities (Ref. PID2019-110356RB-I00/AEI/10.13039/501100011033) to J.F.-I. and E.S. and the Department of Economic and Business Development from Government of Navarra (Ref. 0011-1411-2020-000028 and 0011-1411-2023-000028 to E.S.).
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

Data-driven drug repositioning using olfactory omics profiles: challenges and perspectives in neurodegeneration

  • Cartas Cejudo, Paz
  • Cortés, Adriana
  • Lachén Montes, Mercedes
  • Anaya-Cubero, Elena
  • Fernández Irigoyen, Joaquín
  • Santamaría Martínez, Enrique
Data-driven drug repositioning using olfactory omics profiles – challenges and perspectives in neurodegeneration: Neurodegenerative diseases are characterized by progressive degeneration and loss of neuronal function in the central nervous system. These diseases are often characterized as proteinopathies, which are disorders primarily driven by the aggregation or misfolding of specific amyloid proteins within cells, leading to their dysfunction and eventual death. Despite the gain-of-function hypothesis related to the aggregation of these proteins, recently, an alternative hypothesis regarding the loss-of-function of the soluble monomeric proteins during the process of aggregation into amyloids is gaining currency., This work was funded by grants from the Spanish Ministry of Science, Innovation and Universities (Ref. PID2019-110356RB-I00/AEI/10.13039/501100011033) to JFI and ES and the Department of Economic and Business Development from Government of Navarra (Ref. 0011-1411-2023-000028 to ES). PCC was supported by a predoctoral fellowship from the Public University of Navarra (UPNA). MLM was supported by a postdoctoral fellowship from Miguel Servet Foundation-Navarrabiomed. EAC was supported by 'Programa MRR Investigo 2023' in the framework of the European Union recovery and resilience facility.